The Effect of Insulin on Doxorubicin Induced Cell Death in Luminal A T-47D Breast Cancer Cells
DOI:
10.29303/jbt.v26i4.13514Published:
2026-10-19Downloads
Abstract
Breast cancer is one of the most common malignancies among women worldwide. Luminal A is a prevalent molecular subtype of breast cancer, and doxorubicin is one of the chemotherapeutic agents used in its treatment. However, reduced sensitivity to chemotherapy remains a challenge. Insulin may promote cancer cell survival and potentially influence the cytotoxic effects of anticancer agents. This study aimed to investigate the effect of insulin supplementation on doxorubicin-induced cell death in T-47D luminal A breast cancer cells. An in vitro experimental study was conducted using T-47D cells treated with doxorubicin at concentrations of 3.13, 6.25, 12.5, 25, 50, and 100 μg/mL, with and without insulin supplementation. Cell viability was assessed using the MTT assay, and cell death was estimated from the assay results. Data were analyzed using a paired-samples t-test to compare treatment groups and linear regression to evaluate the relationship between doxorubicin concentration and the percentage of cell death. The results showed that the percentage of cell death increased with increasing doxorubicin concentrations. However, insulin-supplemented cells consistently exhibited lower percentages of cell death than cells treated with doxorubicin alone across all tested concentrations. These findings suggest that insulin supplementation is associated with reduced doxorubicin-induced cytotoxicity in T-47D breast cancer cells. Further studies are needed to clarify the underlying mechanisms and determine whether this effect contributes to reduced chemotherapy sensitivity.
Keywords:
Breast cancer Cell death Doxorubicin Insulin T-47DReferences
Aka, J. A., & Lin, S.-X. (2012). Comparison of Functional Proteomic Analyses of Human Breast Cancer Cell Lines T-47D and MCF7. PLoSONE, 7(2). https://doi.org/10.1371/journal.pone.0031532
Christidi, E., & Brunham, L. R. (2021). Regulated Cell Death Pathways in Doxorubicin-Induced Cardiotoxicity. Cell Death & Disease, 12(4), 339. https://doi.org/10.1038/s41419-021-03614-x
Dai, X., Cheng, H., Bai, Z., & Li, J. (2017). Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. Journal of Cancer, 8(16), 3131–3141. https://doi.org/10.7150/jca.18457
Durrani, I. A., Bhatti, A., & John, P. (2021). The Prognostic Outcome of “type 2 Diabetes Mellitus and Breast Cancer” Association Pivots on Hypoxia-hyperglycemia Axis. Cancer Cell International, 21(1). https://doi.org/10.1186/s12935-021-02040-5
International Agency for Research on Cancer. (2024). GLOBOCAN 2022: World fact sheet. World Health Organization. https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf
International Agency for Research on Cancer. (2024). GLOBOCAN 2022: Indonesia fact sheet. World Health Organization. https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf
Hinz, N., & Jücker, M. (2019). Distinct Functions of AKT Isoforms in Breast Cancer: a Comprehensive Review. Cell Communication and Signaling, 17(1). https://doi.org/10.1186/s12964-019-0450-3
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023). Doxorubicin-an Agent with Multiple Mechanisms of Anticancer Activity. Cells (Basel, Switzerland), 12(4), 659. https://doi.org/10.3390/cells12040659
Kheradmand, P., Vallian Boroojeni, S., & Esmaeili-Mahani, S. (2021). MiR-221 Expression Level Correlates with Insulin-Induced Doxorubicin Resistance in MCF-7 Breast Cancer Cells. Cell Journal, 23(3), 329–334. https://doi.org/10.22074/cellj.2021.7153
Li, Q., Li, Z., Luo, T., & Shi, H. (2022). Targeting The PI3K/AKT/mTOR and RAF/MEK/ERK Pathways for Cancer Therapy. Molecular Biomedicine, 3(1), 47. https://doi.org/10.1186/s43556-022-00110-2
Liambo, I. S., Frisitiohady, A. & Malaka, M. H., 2022. Review: Patofisiologi, Epidemiologi, dan Lini Sel Kanker Payudara. Pharmauho: Jurnal Farmasi, Sains, dan Kesehatan, 8(1), pp. 17-22. https://doi.org/10.33772/pharmauho.v8i
Lykhova, O., Zavelevich, M., Philchenkov, A., Vidasov, N., Kozak, T., Lozovska, Y., Andrusyshyna, I., Bishayee, A., Borikun, T., Lukianova, N., & Chekhun, V. (2023). Does Insulin Make Breast Cancer Cells Resistant to Doxorubicin Toxicity? Naunyn-Schmiedeberg’s Archives of Pharmacology, 396(11), 3111–3122. https://doi.org/10.1007/s00210-023-02516-3
Meredith, A.-M., & Dass, C. R. (2016). Increasing Role of The Cancer Chemotherapeutic Doxorubicin in Cellular Metabolism. The Journal of Pharmacy and Pharmacology, 68(6), 729–741. https://doi.org/10.1111/jphp.12539
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020). PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: from Molecular Landscape to Clinical Aspects. International Journal of Molecular Sciences, 22(1), E173. https://doi.org/10.3390/ijms22010173
Owolabi, M. S., Berinyuy, E. B., & Abdulkabir, A. O. (2025). The Interplay Between Breast Cancer and Diabetes Mellitus: Shared Mechanisms, Risk Factors, and Integrated Management Strategies. BIOMED Natural and Applied Science, 5(1), 1–18. https://doi.org/10.53858/bnas05010118%20
Pliszka, M., & Szablewski, L. (2024). Associations Between Diabetes Mellitus and Selected Cancers. International Journal of Molecular Sciences, 25(13), 7476. https://doi.org/10.3390/ijms25137476
WHO. (2019). Breast Tumours. In International Agency for Research on Cancer.
WHO. (2024). Breast Cancer. Retrieved January, 20, 2025, from https://www.who.int/news-room/fact-sheets/detail/breast-cancer
Zeinoddini, S., Nabiuni, M., & Jalali, H. (2019). The Synergistic Cytotoxic Effects of Doxorubicin and Viola Odorata Extract on Human Breast Cancer Cell Line T47-D. Journal of Cancer Research and Therapeutics, 15(5), 1073–1079. https://doi.org/10.4103/jcrt.JCRT_990_17
Zhang, X., Sheng, X., Miao, T., Yao, K., & Yao, D. (2019). Effect of Insulin on Thyroid Cell Proliferation, Tumor Cell Migration, and Potentially Related Mechanisms. Endocrine Research, 44(1–2), 55–70. https://doi.org/10.1080/07435800.2018.1522641
License
Copyright (c) 2026 Raden Roro Rianti Yusuf, Novrita Padauleng, Fathul Djannah

This work is licensed under a Creative Commons Attribution 4.0 International License.

Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.























